Status:
COMPLETED
Biomarker Testing and DNA Collection in Subjects Participating in Protocol 22001
Lead Sponsor:
Seaside Therapeutics, Inc.
Conditions:
Fragile X Syndrome
Eligibility:
All Genders
6-40 years
Brief Summary
The subjects that meet the inclusion and exclusion criteria and consent to participate in protocol 22001 will be offered participation in 22001A which will evaluate secreted protein before and after t...
Eligibility Criteria
Inclusion
- Subjects that meet the inclusion and exclusion criteria and consent to participate in protocol 22001
Exclusion
- Subjects that meet the inclusion and exclusion criteria and consent to participate in protocol 22001
Key Trial Info
Start Date :
January 1 2009
Trial Type :
OBSERVATIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00823368
Start Date
January 1 2009
Last Update
July 31 2013
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Southwest Autism Research & Resource Center
Phoenix, Arizona, United States, 85006
2
University of California-Los Angeles Neuropsychiatric Institute
Los Angeles, California, United States, 90024
3
M.I.N.D. Institute
Sacramento, California, United States, 95817
4
Rush University Medical Center
Chicago, Illinois, United States, 60612